Skip to main content
Clinical Trials/NCT02473159
NCT02473159
Unknown
Phase 2

Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer: Interventional Pilot Study for 5 Patients

National Cancer Center, Korea1 site in 1 country5 target enrollmentMarch 2015

Overview

Phase
Phase 2
Intervention
indocyanine green
Conditions
Breast Cancer
Sponsor
National Cancer Center, Korea
Enrollment
5
Locations
1
Primary Endpoint
detection rate
Last Updated
10 years ago

Overview

Brief Summary

Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has been used for breast cancer surgery such as sentinel lymph node (SLN) mapping and breast cancer localization.

In this study, our hypothesis are as following:

  1. As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
  2. indocyanine green (ICG) permitted accurate preoperative and intraoperative detection of the SLNs as well as nonpalpable benign brest lesion in patients with breast cancer.

Detailed Description

Indocyanine green, ICG (ICG-fluorescence) * ICG is the most commonly used fluorophore which approve by FDA. * NIR-F imaging with ICG could be used in various surgeries. For example, SLN mapping in breast cancer and localization of liver metastasis, especially superficial lesion * Contains sodium iodide, patients who have history of allergy to iodides should be used as caution. Nonpalpable benign brest lesion localization * New method for the localization and resection of non-palpable breast lesions. * The breast lesion was correctly localized, and the area of ICG corresponded well to the site of the lesions.

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
December 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

So-Youn Jung

Medical Doctor

National Cancer Center, Korea

Eligibility Criteria

Inclusion Criteria

  • nonpalpable breast tumor ≤ 2cm in patients with breast cancer.
  • patients who need breast biopsy as treatment for breast cancer.
  • Eastern Cooperative Oncology Group Performance status 0 or 1
  • consented patients with more than 20 years, less than 70 years

Exclusion Criteria

  • nonpalpable breast tumor ≥ 2cm in patients with breast cancer.
  • pregnancy
  • history of severe allergy to ICG(Indocyanine Green)
  • iode hypersensitiveness

Arms & Interventions

indocyanine green

As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.

Intervention: indocyanine green

Outcomes

Primary Outcomes

detection rate

Time Frame: one day

after complete resection with intraoperative ultrasound confirmed the lesion

Secondary Outcomes

  • determine the pathological stability(one day)

Study Sites (1)

Loading locations...

Similar Trials